April 19, 2023

Joel Lewis Chief Executive Officer and President GALECTIN THERAPEUTICS INC 4960 Peachtree Industrial Blvd., Suite 240 Norcross, GA 30071

Re: GALECTIN

THERAPEUTICS INC

2023

Statement on Form S-3

Registration

Filed April 14,

Please contact Arzhang

File No. 333-271278

Dear Joel Lewis:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Navai at 202-551-4676 with any questions.

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc:

Brian Lee